Executive Summary
Higher Evolut PRO implant depths cut permanent pacemaker rates from 20.3% to 2.3% at one year without trading off mortality, stroke, or valve migration in the final Optimize PRO core-lab analysis (N=603, JACC Cardiovascular Interventions) — a finding that materially strengthens the procedural case for self-expanding TAVR in patients where conduction injury was the main remaining liability. Meanwhile, CMS reopened the National Coverage Analysis for TAVR (CAG-00430R2), and a JACC Cardiovascular Interventions analysis tied transcatheter tricuspid replacement stent geometry to hypoattenuated leaflet thickening — which complicates the case for early TTVR adoption outside experienced centers.
- Optimize PRO: implants >5mm below the annulus dropped PPI to ~2.3% vs 20.3% shallow, with comparable migration and 1-year death/stroke (JACC CV Interv).
- CMS opened a fresh National Coverage Analysis on TAVR, the first major federal coverage revisit since the 2019 expansion (CMS).
- TTVR stent geometry correlates with subclinical leaflet thrombosis on CT — early signal that needs aggressive surveillance in the EVOQUE real-world cohort (JACC CV Interv).
- UCHealth Parkview in Pueblo is discontinuing select cardiothoracic surgeries, the latest example of rural surgical access erosion in valve disease (KOAA News 5).
- Anteris Technologies (AVR.AX) jumped 8.7% to AUD $12.50 and is up 103% over six months as DurAVR data continues to attract structural heart investor attention.
What to watch: Medtronic reports earnings June 3 — Evolut volumes and TAVR market share will set the read-through tone heading into the CMS NCA comment window.
Aortic Valve (TAVR/TAVI)
Higher TAVR implants are the new procedural standard for self-expanding valves, and the final Optimize PRO core-lab analysis in JACC Cardiovascular Interventions makes the case empirically. Across 603 Evolut PRO/PRO+ patients stratified by non-coronary cusp depth, going from <1mm to >5mm dropped permanent pacemaker implantation from 20.3% to 2.3% at one year, with no signal of higher valve migration (0% vs 1.3%, P=0.63) and comparable 1-year death-or-stroke (8.1% vs 12.5%, P=0.40). Shorter hospital stays and less resheathing tracked with depth. [NOTABLE] The trade-off is the unanswered durability question: higher implants reduce the available neo-skirt for future valve-in-valve and may shift commissural alignment — issues the authors flag for future redo-TAVR analysis. This matters most where ESC 2025 has now pushed TAVI to Class I for tricuspid AS patients ≥70 with suitable transfemoral anatomy, while ACC/AHA 2020 still holds the line at >80 or life expectancy <10 years. Optimize PRO is prospective, multicenter, and core-lab adjudicated — but it is single-arm, non-randomized, and Medtronic-sponsored. Surgical comparators remain unchanged: SAVR retains ACC/AHA Class I status under 65 on durability grounds, particularly for patients in whom future reintervention pathways are uncertain. Separately, CMS opening a new TAVR National Coverage Analysis is the first federal coverage revisit since the 2019 expansion to low-risk patients — the comment window will draw heavy industry and Heart Team input on Heart Team composition, volume thresholds, and asymptomatic indications.
Tricuspid Valve (TriClip, TTVR)
Transcatheter tricuspid replacement has a CT problem. A new JACC Cardiovascular Interventions analysis links TTVR stent geometry to hypoattenuated leaflet thickening (HALT) and reduced leaflet motion — the same subclinical thrombosis signal that plagued early TAVR. Abstract details are limited, but the implication is straightforward: as TTVR diffuses outside pivotal-trial centers following the recent STS/ACC TVT registry analysis showing 98.4% implant success and 3.1% 30-day mortality with EVOQUE, leaflet surveillance protocols and anticoagulation strategy will define whether real-world durability matches the trial signal. ESC 2025 already moved transcatheter TV treatment to Class IIa LOE A for high-risk symptomatic severe TR based on TRILUMINATE, Tri.Fr, and TRISCEND II — but the durability data underneath that recommendation is short. ACC/AHA 2020 said nothing about transcatheter TV therapy because the trials hadn't reported yet. Surgical context: contemporary isolated TV surgery mortality has fallen from historical 8-20% with earlier referral, and ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I. The question for 2026 is whether HALT in TTVR is a procedural artifact of stent geometry — fixable — or a structural feature of the platform.
Regulatory & Policy
CMS opened National Coverage Analysis CAG-00430R2 for TAVR, reopening the 2019 NCD that established the two-surgeon Heart Team requirement, site volume thresholds (≥50 TAVRs/year for established programs), and the low-risk expansion. The reanalysis comes as EARLY TAVR has pushed early intervention in asymptomatic severe AS into ESC 2025 Class IIa territory and as longer-term TAVR durability data continue to accumulate. Watch for proposals on asymptomatic indications, Heart Team composition, and whether volume thresholds are revised given the procedural maturation of TAVR. [NOTABLE] Industry coverage and reimbursement strategy across Edwards, Medtronic, Boston Scientific, and Abbott will be shaped by what comes out of this comment window.
Industry & Market
UCHealth Parkview in Pueblo, Colorado announced it will discontinue some cardiothoracic surgeries this month. The story is local but the pattern is national: rural and mid-market surgical capacity is shrinking just as the field debates whether TAVR-eligible patients deserve a Heart Team that includes a surgeon who actually operates. CMS's NCA revisit will land in an environment where the surgical comparator is increasingly hard to access geographically — a tension the guidelines do not address.
Financial Analysis
Anteris Technologies (AVR.AX) is up 103% over six months as DurAVR continues to draw investor attention to single-piece bioprosthetic designs, while the large-cap valve names diverge sharply. Edwards is the clear outperformer (+4% over six months, sole positive name in the cohort) as the TAVR-pure-play thesis holds. Medtronic (-26%) and Abbott (-30%) reflect broader diversified medtech weakness rather than valve-specific signal. Boston Scientific's -52% six-month drawdown is the standout — sentiment around TriClip uptake and EVOQUE TTVR competitive dynamics will hinge on whether today's HALT signal in TTVR spreads. Edwards CFO Theodora Mistras filed an initial Form 3 on June 1, a routine insider disclosure following her appointment. Sell-side analysts see 11.78% upside to consensus on EW.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $88.16 (+1.95% daily); 6-month +4.07%; 52-week range $72.30 – $89.14 (trading at the top of the range)
- Market cap: $50.8B | Trailing P/E 47.65 | Forward P/E 26.18 | Beta 0.87
- Analyst target: $96.65 (range $84 – $110, 26 analysts); consensus Buy
- Next earnings: July 23, 2026 (EPS est $0.74; revenue est $1.70B)
- Commentary: Pure-play structural heart exposure is now the cleanest TAVR/TTVR/M-TEER trade. SAPIEN volumes and EVOQUE TTVR ramp will dominate the July call. The Optimize PRO depth data is a Medtronic story but reinforces that procedural refinement is still moving TAVR forward — generally bullish for the category.
Medtronic (MDT)
- Price: $73.98 (+0.23% daily); 6-month -26.36%; 52-week range $73.67 – $106.33 (trading at 52-week low)
- Market cap: $95.0B | Trailing P/E 20.66 | Forward P/E 12.21 | Beta 0.63
- Analyst target: $106.56 (range $84 – $121, 25 analysts); consensus Buy
- Next earnings: June 3, 2026 (EPS est $1.55; revenue est $9.61B) — TOMORROW
- Commentary: Stock sits at the low. Earnings will be the test: Evolut TAVR commentary in light of today's Optimize PRO data, plus any read on the CMS NCA, will set near-term direction.
Abbott (ABT)
- Price: $87.78 (+2.55% daily); 6-month -29.72%; 52-week range $81.97 – $139.06
- Market cap: $152.9B | Trailing P/E 24.59 | Forward P/E 14.48 | Beta 0.65
- Analyst target: $117.29 (range $92 – $135, 24 analysts); consensus Buy
- Next earnings: July 16, 2026 (EPS est $1.28; revenue est $12.53B)
- Commentary: MitraClip and TriClip remain the structural heart drivers, but valve revenue is dwarfed by diagnostics and nutrition in the consolidated story. TriClip uptake is the relevant signal here.
Boston Scientific (BSX)
- Price: $47.98 (-0.68% daily); 6-month -51.55%; 52-week range $47.35 – $109.50 (at 52-week low)
- Market cap: $71.3B | Trailing P/E 20.08 | Forward P/E 12.84 | Beta 0.62
- Analyst target: $79.37 (range $55 – $106, 30 analysts); consensus Strong Buy
- Next earnings: July 29, 2026 (EPS est $0.83; revenue est $5.38B)
- Commentary: The 52% six-month drawdown is the outlier in the cohort. Sell-side still rates Strong Buy with target near $80, implying material disconnect. Today's TTVR HALT signal in JACC CV Interv affects the structural heart pipeline narrative.
Anteris Technologies (AVR.AX)
- Price: AUD $12.50 (+8.70% daily); 6-month +102.92%; 52-week range $4.68 – $13.80
- Market cap: $1.2B | Forward P/E -5.73 (pre-revenue) | Beta 0.59
- Analyst target: $13.00 (single analyst)
- Commentary: DurAVR single-piece biomimetic valve continues to drive momentum. The 103% six-month run reflects investor appetite for a differentiated TAVR platform, but the company remains pre-revenue with limited analyst coverage. Pivotal trial readout timing is the next catalyst.
Market outlook: The cohort is bifurcating. Pure-play structural heart exposure (EW, AVR.AX) is outperforming diversified medtech (MDT, ABT, BSX) on a 6-month basis. The CMS NCA reopening is a category-level event that will affect all of them, but the magnitude depends on whether the rewrite tightens or loosens Heart Team and volume requirements. Tomorrow's MDT print is the first read.
Clinical Trial Updates
One non-valve-specific trial registry update today; the structural heart pivotal pipeline (REPAIR-MR, PRIMARY, TRILUMINATE, CLASP TR, APOLLO, TRISCEND II) did not record new status changes.
- Heart Failure / Body Composition: NCT07619222 — "Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Heart Failure Subtypes." Status: Not yet recruiting. N=1000. Sponsor: Beijing Anzhen Hospital. Observational; relevance to valve disease is indirect but matters for HFpEF/atrial functional MR phenotyping that ESC 2025 now formally recognizes.
What's next: Medtronic earnings June 3 will provide the first CFO-level commentary on the CMS NCA reopening and how Optimize PRO data is being deployed in Evolut field training — both shape Q3 TAVR momentum going into the AHA late-breaking cycle.